Cargando…

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure

AIMS: The clinically investigated rationale for neprilysin (NEP)‐inhibition by angiotensinreceptor‐NEPinhibitor (ARNi) therapy is to induce elevations in endogenous natriuretic peptides. NEP, however, cleaves a broad spectrum of substrates, which partially hold significant implications in heart fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arfsten, Henrike, Goliasch, Georg, Bartko, Philipp E., Prausmüller, Suriya, Spinka, Georg, Cho, Anna, Novak, Johannes, Haslacher, Helmuth, Strunk, Guido, Struck, Joachim, Hülsmann, Martin, Pavo, Noemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328655/ https://www.ncbi.nlm.nih.gov/pubmed/32598074 http://dx.doi.org/10.1111/bcp.14442

Ejemplares similares

Neprilysin inhibition does not alter dynamic of proenkephalin‐A 119‐159 and pro‐substance P in heart failure
por: Arfsten, Henrike, et al.
Publicado: (2021)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020)

Relevance of Neutrophil Neprilysin in Heart Failure
por: Prausmüller, Suriya, et al.
Publicado: (2021)

Neprilysin as a Biomarker: Challenges and Opportunities
por: Pavo, Noemi, et al.
Publicado: (2020)

Circulating dipeptidyl peptidase (cDPP3)—A marker for end‐stage heart failure?
por: Pavo, Noemi, et al.
Publicado: (2022)

Neutrophil Activation/Maturation Markers in Chronic Heart Failure with Reduced Ejection Fraction
por: Prausmüller, Suriya, et al.
Publicado: (2022)

Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic
por: Han, Emilie, et al.
Publicado: (2023)

Malnutrition outweighs the effect of the obesity paradox
por: Prausmüller, Suriya, et al.
Publicado: (2022)

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus
por: Prausmüller, Suriya, et al.
Publicado: (2021)

Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure
por: Pavo, Noemi, et al.
Publicado: (2019)

Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study
por: Bartko, Philipp E, et al.
Publicado: (2021)

An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation
por: Spinka, Georg, et al.
Publicado: (2020)

Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer
por: Arfsten, Henrike, et al.
Publicado: (2021)

Secondary mitral regurgitation—Insights from microRNA assessment
por: Spinka, Georg, et al.
Publicado: (2020)

Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2019)

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients
por: Pavo, Noemi, et al.
Publicado: (2019)

The inflammation‐based modified Glasgow prognostic score is associated with survival in stable heart failure patients
por: Cho, Anna, et al.
Publicado: (2020)

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
por: Anker, Markus S., et al.
Publicado: (2020)

GDF‐15 in solid vs non‐solid treatment‐naïve malignancies
por: Arfsten, Henrike, et al.
Publicado: (2019)

Metabolomics implicate eicosanoids in severe functional mitral regurgitation
por: Hofbauer, Thomas M., et al.
Publicado: (2022)

Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction
por: Pavo, Noemi, et al.
Publicado: (2018)

A streamlined, machine learning-derived approach to risk-stratification in heart failure patients with secondary tricuspid regurgitation
por: Heitzinger, Gregor, et al.
Publicado: (2023)

Soluble neprilysin and survival in critically ill patients
por: Lenz, Max, et al.
Publicado: (2022)

Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation
por: Pavo, Imre J., et al.
Publicado: (2020)

Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
por: Boutagy, Nabil E., et al.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data
por: Frey, Maria Klara, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor
por: Kim, Moo Jun, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
por: Li, Wanjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_76jkrkarbmu05uqjj3b7sa43bv